UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of: October 2024

Commission File Number: 001-39152

QUANTUM BIOPHARMA LTD.

(Translation of registrant's name into English)

55 University Avenue, Suite 1003

Toronto, Ontario M5L 2H7, Canada

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒     Form 40-F ☐

INCORPORATION BY REFERENCE

This Form 6-K and Exhibit 99.1 attached hereto are incorporated by reference into the Registrant’s Registration Statement on Form F-3 (SEC File No. 333-276264), including any prospectuses forming a part of such Registration Statement.

EXPLANATORY NOTE

On October 21, 2024, Quantum BioPharma Ltd. issued a press release titled “Quantum Biopharma (Nasdaq: Qntm) Files A Us Federal Lawsuit Against Cibc World Markets, Rbc Dominion Securities And Others, Seeking Damages In Excess Of $700,000,000 Usd, For Possible Stock Price Manipulation/Spoofing”  A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by this reference.

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Quantum BioPharma Ltd. (Registrant)
Date: October 21, 2024	By:	/s/ Donal Carroll
		Donal Carroll, Chief Financial Officer

3

EXHIBIT INDEX

Exhibit	Description
Exhibit 99.1	Press Release dated October 21, 2024

4